dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Schmutzler, Rita |
dc.contributor.author | Schmitz-Luhn, Bjoern |
dc.contributor.author | Borisch, Bettina |
dc.contributor.author | Devilee, Peter |
dc.contributor.author | Eccles, Diana M |
dc.contributor.author | Hall, Per |
dc.contributor.author | Balmaña Gelpí, Judith |
dc.date.accessioned | 2022-09-12T08:56:17Z |
dc.date.available | 2022-09-12T08:56:17Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, et al. Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors. Breast Care. 2022 Apr;17(2):208–23. |
dc.identifier.issn | 1869-6961 |
dc.identifier.uri | https://hdl.handle.net/11351/8144 |
dc.description | Breast cancer; Evidence-generating care; Risk-adjusted prevention |
dc.description.abstract | Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept. |
dc.language.iso | eng |
dc.publisher | Karger Publishers |
dc.relation.ispartofseries | Breast Care;17(2) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Factors de risc |
dc.subject | Mama - Càncer - Prevenció |
dc.subject | Mama - Càncer - Diagnòstic |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /prevention & control |
dc.subject.mesh | Early Detection of Cancer |
dc.subject.mesh | Risk Factors |
dc.title | Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors |
dc.type | info:eu-repo/semantics/article |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /prevención & control |
dc.subject.decs | detección precoz del cáncer |
dc.subject.decs | factores de riesgo |
dc.relation.publishversion | https://doi.org/10.1159/000517182 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Schmutzler RK] Center Familial Breast and Ovarian Cancer and Center of Integrated Oncology (CIO), University Hospital Cologne, Cologne, Germany. [Schmitz-Luhn B] Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health (ceres), University of Cologne, and Research Unit Ethics, University Hospital of Cologne, Cologne, Germany. [Borisch B] Institute of Global Health, University of Geneva, Geneva, Switzerland. [Devilee P] Leids Universitair Medisch Zentrum, Universiteit Leiden, Leiden, The Netherlands. [Eccles D] Clinical Trials Unit, University of Southampton, Southampton, UK. [Hall P] Karolinska Institutet, Stockholm, Sweden. [Balmaña J] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 35702492 |
dc.identifier.wos | 10.1159/000517182 |
dc.identifier.wos | 000811438400003 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/634935 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |